DIARRHOEA is the #1 most commonly reported adverse reaction for CABOZANTINIB, manufactured by Exelixis, Inc.. There are 8,862 FDA adverse event reports linking CABOZANTINIB to DIARRHOEA. This represents approximately 7.9% of all 112,838 adverse event reports for this drug.
Patients taking CABOZANTINIB who experience diarrhoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
Reporting Frequency
DIARRHOEA8,862 of 112,838 reports
DIARRHOEA is moderately reported among CABOZANTINIB users, representing a notable but not dominant share of adverse events.
Other Side Effects of CABOZANTINIB
In addition to diarrhoea, the following adverse reactions have been reported for CABOZANTINIB:
DIARRHOEA has been reported as an adverse event in 8,862 FDA reports for CABOZANTINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
How common is DIARRHOEA with CABOZANTINIB?
DIARRHOEA accounts for approximately 7.9% of all adverse event reports for CABOZANTINIB, making it one of the most commonly reported side effect.
What should I do if I experience DIARRHOEA while taking CABOZANTINIB?
If you experience diarrhoea while taking CABOZANTINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.
Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.